News

Core Life Analytics Closes €1M Series A Deal

- The Netherlands-based data analytics company, Core Life Analytics, has closed a €1m Series A financing round. The investor team is composed of BOM Brabant Ventures, Utrecht Holdings and TechFund One.

Organon Returns to The Netherlands

- De bedrijfsnaam Organon keert terug in Nederland. Dat is het resultaat van overleg tussen de MSD-directie in Nederland en de Landelijke Ondernemingsraad die hierover advies moest uitbrengen. Vanuit de ondernemingsraad is er groen licht voor uitvoering en vervolgstappen in Nederland.

LUMC Constructs the Largest Stem Cell Facility for The Netherlands and Beyond

- Leiden University Medical Center (LUMC) will start this year with the construction of the largest non-profit stem cell and gene therapy facility in the Netherlands, and one of the largest facilities in Europe. In the ‘NECSTGEN’ facility, the Netherlands Centre for the Clinical advancement of Stem Cell and Gene Therapies, research will be conducted in the field of regenerative medicine.

WHO Summit Confirms Global Approach COVID-19

- Op de jaarvergadering van de Wereldgezondheidsorganisatie WHO hebben meer dan 130 landen een resolutie aangenomen om gezamenlijk de wereldwijde coronapandemie te bestrijden.

BOM Invests in Haermonics for Better Care After Open Heart Surgery

- Haermonics, een spin-off van Amsterdam UMC, heeft de effectiviteit en veiligheid bewezen van het spoelen van het hartzakje na een openhartoperatie. Een experimentele opstelling zorgde voor significant minder bloedingsgerelateerde complicaties.

First Clinical Trial with Genetically Modified Malaria Vaccine Completed

- In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.

Project recovery during the COVID-19 crisis

- The outbreak of COVID-19 and the measures taken against it have raided us all. The closure of many laboratories, the (temporary) termination of clinical research, etcetera can have effects on, among other things, the execution, duration and financing of the research. This situation requires flexibility and creativity. Top Sector Life Sciences & Health (Health~Holland) feels a joint responsibility for finding solutions to ensure good progress and completion of all studies.

Three More Projects Awarded in COVID-19 Call

- COVID-19 was officially declared a pandemic on 11 March 2020. To prevent the disease from spreading, research projects have been set up at a rapid pace. Top Sector Life Sciences & Health has taken quick action to set up a COVID-19 call at the end of March. Three more projects have been awarded and are granted PPP Allowance to start their research.

Results: Impact of COVID-19 on Life Sciences Industry

- This month ttopstart has interviewed 50 European life sciences companies on how they are impacted by and have responded to the COVID-19 crisis. In the report the results are discussed and translated into recommendations.

Second Coronavirus Call for an Expression of Interest

- This second call for an expression of interest complements the first expression of interest that the European Commission published in January 2020, which led to the funding of 18 projects in March 2020. The first expression of interest focused on advancing the knowledge on SARS-CoV-2 and its impact on infected persons, with the aim of contributing to an efficient patient management and/or public health preparedness and response.